Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine
Authors:
- 4 February 2010
- journal article
- case report
- Published by Springer Nature in Clinical Rheumatology
- Vol. 29 (4) , 443-445
Abstract
A 58-year-old male was admitted to our hospital because of periungual nailfold an erythema and erythematous rash on the dorsal joints of his hands and feet, but no muscle weakness. He was thus diagnosed to have amyopathic dermatomyositis. He had moderate hypoxemia and his chest computed tomography scans demonstrated bilateral ground-glass opacities, implicating complication with interstitial pneumonia. Therapy was initiated with pulsed methylprednisolone followed by high-dose corticosteroids, pulsed cyclophosphamide, and cyclosporine. The skin manifestations improved; however, the pulmonary infiltrates and hypoxemia deteriorated during the 2-month period of the treatment. The treatment was switched from cyclosporine to tacrolimus because of an inadequate clinical response to the therapy, and this resulted in the resolution of interstitial pneumonia. This case indicates that tacrolimus administration should be considered for patients with this life-threatening disorder when it is judged to be refractory to cyclosporine.Keywords
This publication has 13 references indexed in Scilit:
- Interstitial lung disease associated with amyopathic dermatomyositis: Review of 18 casesRespiratory Medicine, 2007
- Interstitial lung diseases associated with amyopathic dermatomyositisEuropean Respiratory Journal, 2006
- Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositisClinical Rheumatology, 2005
- Treatment of antisynthetase‐associated interstitial lung disease with tacrolimusArthritis & Rheumatism, 2005
- Potentially fatal interstitial lung disease can occur in clinically amyopathic dermatomyositisJournal of the American Academy of Dermatology, 2003
- Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?Journal of the American Academy of Dermatology, 2002
- Conversion from cyclosporin A to tacrolimus is safe and decreases blood pressure, cholesterol levels and TGF-β1 type I receptor expressionClinical Transplantation, 2001
- Tacrolimus in refractory poly myositis with inter stitial lung diseaseThe Lancet, 1999
- Role of transforming growth factor-β1 in experimental chronic cyclosporine nephropathyKidney International, 1996
- A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilinNature, 1989